LFA Lugano Financial Advisors SA Has $80,000 Stock Position in Pfizer Inc. (NYSE:PFE)

LFA Lugano Financial Advisors SA lessened its stake in Pfizer Inc. (NYSE:PFE) by 25.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned 3,000 shares of the biopharmaceutical company’s stock after selling 1,000 shares during the quarter. LFA Lugano Financial Advisors SA’s holdings in Pfizer were worth $80,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. PSI Advisors LLC boosted its stake in Pfizer by 1.4% in the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company’s stock worth $738,000 after purchasing an additional 385 shares during the period. Waddell & Associates LLC lifted its holdings in shares of Pfizer by 1.6% in the third quarter. Waddell & Associates LLC now owns 24,978 shares of the biopharmaceutical company’s stock valued at $723,000 after purchasing an additional 388 shares in the last quarter. Patriot Financial Group Insurance Agency LLC boosted its position in shares of Pfizer by 1.0% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company’s stock worth $1,027,000 after buying an additional 391 shares during the period. D Orazio & Associates Inc. raised its position in Pfizer by 5.5% in the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock valued at $200,000 after buying an additional 391 shares during the last quarter. Finally, Lipe & Dalton lifted its stake in Pfizer by 17.7% in the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock valued at $71,000 after acquiring an additional 400 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Insider Activity

In other news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.06% of the stock is owned by company insiders.

Pfizer Trading Down 1.0 %

Shares of Pfizer stock opened at $25.73 on Thursday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business has a fifty day simple moving average of $26.28 and a two-hundred day simple moving average of $27.18. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a market capitalization of $145.79 billion, a price-to-earnings ratio of 18.24, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter last year, the company posted $0.10 EPS. Pfizer’s quarterly revenue was up 24.7% compared to the same quarter last year. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on PFE shares. Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Wednesday. UBS Group lowered their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Citigroup decreased their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Finally, Truist Financial dropped their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.